View Older Stories View More Recent Stories

Jun 6, 2022 07:48AM MedMira Receives Patent for its Unique Quantitative Diagnostic System
May 27, 2022 08:01AM MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
May 20, 2022 08:52AM VYRA™ Product Line Update
May 12, 2022 08:40AM MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
Mar 31, 2022 10:00PM MedMira Reports Second Quarter Results FY2022
Mar 9, 2022 08:17AM MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
Feb 8, 2022 09:00PM MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test
Feb 4, 2022 07:16AM MedMira Provides a Pre-Annual General Meeting Update
Dec 30, 2021 10:00PM MedMira Reports First Quarter Results FY2022
Dec 21, 2021 09:00PM MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities
Dec 17, 2021 07:53AM MedMira strengthen its Board with New Appointment
Dec 14, 2021 08:00PM MedMira announces significant debt reduction and additional growth capital
Nov 30, 2021 10:00PM MedMira Reports FY2021 Fourth Quarter and Year End Financial Results
Jul 14, 2021 10:30PM MedMira Closes New Equity Investment for Future Growth
Jun 29, 2021 10:00PM MedMira Reports Third Quarter Results FY2021
Jun 15, 2021 09:03AM Performance Update on World Health Organisation SARS-CoV2 Serology Standards
Mar 31, 2021 10:00PM MedMira Reports Second Quarter Results FY2021
Mar 3, 2021 07:28AM Product and Regulatory Update on MedMira’s COVID-19 Product Family
Jan 29, 2021 08:43PM Progress Update on MedMira’s COVID-19 Product Family
Dec 30, 2020 09:00PM MedMira Announces Product Update
Dec 24, 2020 07:00PM MedMira Reports First Quarter Results FY2021
Nov 30, 2020 07:00PM MedMira Reports FY2020 Fourth Quarter and Year End Financial Results
Oct 7, 2020 09:28AM MedMira reports additional independent performance evaluation results of REVEALCOVID-19™ Total Antibody Test
Sep 3, 2020 05:00PM REVEALCOVID-19™ Total Antibody Test Sensitivity and Cross-Reactivity Analysis
Jul 10, 2020 09:48AM MedMira’s July Update as per the IIROC Request
Jun 29, 2020 08:00PM MedMira Reports Third Quarter Results FY2020
May 27, 2020 01:00PM MedMira Announces Exclusive Distribution Partnership with Webb Diagnostic Technologies and Initial Order for REVEALCOVID-19™ Total Antibody Test in the U.S.
May 21, 2020 12:26PM MedMira Announces Progress Update of its REVEALCOVID-19™ Total Antibody Test Including CE Mark
Apr 23, 2020 07:00AM MedMira Announces Notification Submission to US FDA Emergency Use Authorization
Apr 15, 2020 08:00PM MedMira Announces Update on Development of Point-of-Care Antibody Test
Mar 31, 2020 06:00PM MedMira Reports Second Quarter Results FY2020
Dec 30, 2019 07:00PM MedMira Reports First Quarter Results FY2020
Nov 28, 2019 08:00PM MedMira Reports 2019 Fourth Quarter and Year End Financial Results
Jun 28, 2019 06:00PM MedMira Reports Third Quarter Results
Jun 3, 2019 06:00PM MedMira Announces AGM Results
Mar 28, 2019 07:00PM MedMira Reports 2018 Fourth Quarter and Year End Financial Results
Mar 14, 2019 06:00PM Management Cease Trade Order Update
Feb 28, 2019 06:00PM Management Cease Trade Order Update
Feb 19, 2019 06:00PM Management Cease Trade Order Update
Feb 5, 2019 06:00PM Management Cease Trade Order Update
Jan 22, 2019 06:00PM Management Cease Trade Order Update
Jan 8, 2019 06:00PM Management Cease Trade Order Update
Dec 28, 2018 06:00PM MedMira Reports First Quarter Results
Dec 25, 2018 06:00PM Management Cease Trade Order Update
Dec 11, 2018 04:15PM Management Cease Trade Order Update
Nov 27, 2018 10:20AM MedMira Inc. Announces Appointment of Auditor and Late Filing of Annual Financial Statements
Sep 6, 2018 09:53AM MedMira Announces Revocation of Cease Trade Order
Jun 29, 2018 07:00PM MedMira Reports Third Quarter Results
Mar 29, 2018 07:00PM MedMira Reports Second Quarter Results
May 1, 2017 06:00AM MedMira Receives CE Mark for Syphilis/HIV Multiplex Rapid Test
View More Recent Stories View Older Stories